LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

just so many bubbles in the air, at least for now

back to 3p then.

not if filled with helium (preferably not hydrogen!)

Im forever blowing bubbles!

nor methane....

Seems PXS has finally settled down after the earlier hysteria which managed to ramp the SP up to an unrealistic level. I do wonder how many got sucked in at much higher levels and are trying to work out whether to take a loss or hang on for the much hyped Coca Cola deal (should it of course ever materialise).

I can't say I have changed my opinion on the prospects of PXS, one or two of these companys come around every year and usually come back to earth with a thud following excessive excitement. 5p looks on the cards, but I guess a half impressive RNS could see it shooting back up again. Reminds me of SEO and their one machine trail with ASDA.

nor methane.....

Tippedd on uk analyst. Evils diary: UK-Analyst.com

Thought he was shorting it? Not that has any particualr relevance

Little pi panickers jump. And the big boys mop up!

EK has shorted at 8.2p, doing well headed for 3p.

Little PI panickers might well have their heads screwed on straight! Time will tell ;)

DAILY EXPRESS TODAY

GOING DUTCH

Health food developer provexis has lined up dutch vitamins giant DSM to market its anti-thrombotic Fruitflow tomato concentrate globally. Provexis boss Stephen Moon, said: "DSM is a very significant player and enjoys companies like coca-cola and unilever as major clients."

Slightly surprised no comments over the weekend, a quite frantic day on Friday elicited by CEO Moon binning 6 million shares, seemingly not demonstrating much confidence in PXS prospects. I would imagine today will be equally volatile.

`

that dot is very meaningful.......lol go on tell us anyway..

Fruit fly on your screen?the expected decimal point? The size of bouncys brain?

+18% Any excitement?

Stephen Moon, CEO of Provexis, commented:



"We are delighted with the results of this latest human trial, which highlight the substantial effect that Fruitflow can have on platelet aggregation, without the associated side effects known to occur with aspirin.



"On 12th February we announced intent to enter into an agreement with DSM Nutritional Products, the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. Today's news provides further strength to the commercialisation plans for Fruitflow and in the planned alliance we anticipate developing multiple routes to market."

9 March 2010

Proof's in the pudding as they say.....more good news, onwards and up we go!!

RNS Number : 2656I
Provexis PLC
09 March 2010
Provexis PLC

("Provexis" or the "Company")

Completion of Aspirin Comparison Human Trial for Fruitflow



Provexis plc (PXS.L), which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, today announces the completion of the human trial comparing the effects of its Fruitflow anti-thrombotic technology with aspirin.

Fruitflow is a patented, scientifically-proven tomato extract which inhibits several pathways involved in platelet aggregation (a process which, if overstimulated can contribute to unwanted clot formation in the bloodstream), a known factor in cause of heart attack, stroke and venous thrombosis, and does so without any side effects.

Aspirin, an anti-inflammatory drug, primarily targets one specific platelet aggregation pathway, and is not recommended for use by the population at large for cardiovascular disease prevention, partly due to its well known side effects which include gastric ulceration and bleeding. In addition, a significant percentage of users show some resistance to its effects.

The trial was undertaken by Provexis at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, with independent statistical analysis by BIOSS, and is the tenth placebo controlled human trial undertaken with the Fruitflow extract. The trial compared the effects of Fruitflow and aspirin over a five hour time course. Interactions between Fruitflow and aspirin when consumed together were also studied. 43 healthy subjects completed the trial over a 7-month period and the results are statistically significant.

Fruitflow showed up to 30% reduction from baseline platelet aggregation in each of three different biological pathways, while a single dose of aspirin caused up to 60% reduction in a single pathway, with lesser effects on the other two. The broader antiplatelet effect of Fruitflow reflects the Company's aim to provide a daily dietary supplement with a significant effect on blood flow, but without suppressing platelet aggregation completely.



The study also showed no negative interactions between Fruitflow and aspirin when consumed together.



The findings are significant and serve to demonstrate the potential effectiveness of Fruitflow as a preventative measure in cardiovascular health through inhibiting platelet aggregation, with no side effects. This trial is an important milestone for the Company as it has worked to develop and patent the technology worldwide while submitting Fruitflow to rigorous scientific and regulatory testing to substantiate efficacy and safety.



Stephen Moon, CEO of Provexis, commented:



"We are delighted with the results of this latest human trial, which highlight the substantial effect that Fruitflow can have on platelet aggregation, without the associated side effects known to occur with aspirin.



"On 12th February we announced intent to enter into an agreement with DSM Nutritional Products, the world's leading supplier of vitamins, carotenoids and other fine chemicals to the feed, food, pharmaceutical and personal care industries. Today's news provides further strength to the commercialisation plans for Fruitflow and in the planned alliance we anticipate developing multiple routes to market."

9 March 2010